2. Academic Validation
  3. ROS-responsive microneedles loaded with integrin avβ6-blocking antibodies for the treatment of pulmonary fibrosis

ROS-responsive microneedles loaded with integrin avβ6-blocking antibodies for the treatment of pulmonary fibrosis

  • J Control Release. 2023 Aug;360:365-375. doi: 10.1016/j.jconrel.2023.03.060.
Hao Ding 1,  Yuan Cui 1,  Jian Yang 1,  Yu Li 1,  Hongtao Zhang 2,  Sheng Ju 1,  Xingyu Ren 3,  Cheng Ding 4,  Jun Zhao 5
Affiliations

Affiliations

  • 1 Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215000, China.
  • 2 Soochow University Laboratory of Cancer Molecular Genetics, Medical College of Soochow University, Suzhou 215000, China.
  • 3 Department of Medical imaging, College of Clinical Medicine, Suzhou Vocational Health College, Suzhou 215000, China.
  • 4 Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215000, China. Electronic address: [email protected].
  • 5 Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215000, China. Electronic address: [email protected].
PMID: 37331606 DOI: 10.1016/j.jconrel.2023.03.060
Abstract

Pulmonary fibrosis (PF) is a fibrotic interstitial pneumonia with poor prognosis and limited treatment methods. Inhibition of Integrin αVβ6 expression could prevent pulmonary fibrosis, however, a phase II clinical trial of αVβ6-blocking antibody treating PF stopped prematurely due to low bioavailability and toxic side effects of systematic administration. Here, we describe a micro-invasive percutaneous transthoracic and hydrogen peroxide-responsive microneedle composed of degradable gel for smart delivery of Integrin αvβ6-blocking antibody which has the advantages of rapid response, excellent biocompatibility, protection of bioactivity, high tissue permeation and specific targeting to lesions. This microneedle could partially release Integrin αvβ6-blocking Antibodies when exposed to hydrogen peroxide generated during PF, thus reducing activation of the pro-fibrotic factor TGF-β1 from its latent precursor and showing excellent therapeutic efficacy for PF.

Keywords

Drug delivery; Integrin αvβ6; Microneedle; Minimally invasive surgery; Pulmonary fibrosis.

Figures
Products